Claire McGroder
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Claire McGroder has a total of 143 co-authors. Here are the top co-authors by number of shared publications:
- Christine Kim Garcia
Division of Pulmonary and Critical Care Medicine, Columbia University, New York, New York
7 shared publications - Matthew R. Baldwin
Columbia University, Vagelos College of Physicians and Surgeons
6 shared publications - David Zhang
Division of Pulmonary, Allergy, and Critical Care, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA
3 shared publications Shannon Benesh
Division of Pulmonary, Allergy, and Critical Care Medicine
3 shared publications- Anjali Saqi
Department of Pathology and Cell Biology Columbia University Irving Medical Center New York NY USA
2 shared publications - Anna J. Podolanczuk
Department of Medicine, Weill Cornell Medicine , New York, NY
2 shared publications
Latest Publications
- 1 November 2025
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
- Vol. 22 (11) , 1654-1663
Imaging, Pulmonary Function, and Histopathologic Findings of Persistent Fibrosis in a Longitudinal Cohort 3 Years after COVID-19
Rationale: Survivors of severe coronavirus disease (COVID-19) frequently have persistent radiologic abnormalities beyond one year. Scant data exist for long-term outcomes of COVID-19. Objectives: To characterize a longitudinal multiethnic cohort of COVID-19 survivors 3 years after infection; to identify clinical factors associated with post–COVID-19 fibrotic-like abnormalities; to describe changes in radiologic abnormalities at 4 months, 15 months, and 3 years; and to describe histopathologic features of lung parenchyma from participants with fibrotic-like abnormalities at 3 years. Methods: One hundred two survivors of severe or critical COVID-19 (50% mechanically ventilated, all requiring oxygen supplementation) from a single-center, prospective, longitudinal, multiethnic cohort completed inspiratory and expiratory high-resolution chest imaging, pulmonary function testing, and physical performance testing 3 years after hospitalization. More than 70% participated in earlier follow up visits at 4 and/or 15 months. Factors associated with persistent fibrotic-like abnormalities were examined using multivariable logistic regression with covariate-balanced propensity scores to estimate adjusted associations. For subjects with more than one imaging study, changes in ground-glass opacities, reticulations, and traction bronchiectasis were semiquantitatively analyzed and qualitatively assessed. Five participants with post–COVID-19 fibrosis scores in the top quartile underwent transbronchial biopsy for histopathologic analysis. Results: Fibrotic-like abnormalities, including reticulations and traction bronchiectasis, were present in 61% of survivors of severe or critical COVID-19. In adjusted analyses, fibrotic-like abnormalities were positively associated with male sex, lower body mass index (BMI), shorter leukocyte telomere length, increased severity of illness and mechanical ventilation; they were negatively associated with Black race. Participants with fibrotic-like abnormalities were more likely to have reduced diffusion capacity and reduced 6-minute-walk distance. Reticulations, as assessed by semiquantitative analysis, modestly improved across all time points, even between 15 months and 3 years. Qualitatively, most participants had stable fibrotic-like abnormalities across all time points, with 9% improving from 15 months to 3 years and none worsening. Lung parenchyma from transbronchial biopsies of five individuals with elevated fibrotic scores showed small airway histopathology, consistent with air trapping during expiration, and infrequent interstitial thickening and fibrosis. Conclusions: Despite modest improvements in radiologic fibrotic-like abnormalities 3 years after hospitalization, their continued presence and their association with reduced diffusion capacity and reduced walk distance highlight the long-term consequences of severe COVID-19, which may require further monitoring.
- 1 November 2025
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
- Vol. 22 (11) , 1654-1663
Imaging, Pulmonary Function, and Histopathologic Findings of Persistent Fibrosis in a Longitudinal Cohort 3 Years after COVID-19
Rationale: Survivors of severe coronavirus disease (COVID-19) frequently have persistent radiologic abnormalities beyond one year. Scant data exist for long-term outcomes of COVID-19. Objectives: To characterize a longitudinal multiethnic cohort of COVID-19 survivors 3 years after infection; to identify clinical factors associated with post–COVID-19 fibrotic-like abnormalities; to describe changes in radiologic abnormalities at 4 months, 15 months, and 3 years; and to describe histopathologic features of lung parenchyma from participants with fibrotic-like abnormalities at 3 years. Methods: One hundred two survivors of severe or critical COVID-19 (50% mechanically ventilated, all requiring oxygen supplementation) from a single-center, prospective, longitudinal, multiethnic cohort completed inspiratory and expiratory high-resolution chest imaging, pulmonary function testing, and physical performance testing 3 years after hospitalization. More than 70% participated in earlier follow up visits at 4 and/or 15 months. Factors associated with persistent fibrotic-like abnormalities were examined using multivariable logistic regression with covariate-balanced propensity scores to estimate adjusted associations. For subjects with more than one imaging study, changes in ground-glass opacities, reticulations, and traction bronchiectasis were semiquantitatively analyzed and qualitatively assessed. Five participants with post–COVID-19 fibrosis scores in the top quartile underwent transbronchial biopsy for histopathologic analysis. Results: Fibrotic-like abnormalities, including reticulations and traction bronchiectasis, were present in 61% of survivors of severe or critical COVID-19. In adjusted analyses, fibrotic-like abnormalities were positively associated with male sex, lower body mass index (BMI), shorter leukocyte telomere length, increased severity of illness and mechanical ventilation; they were negatively associated with Black race. Participants with fibrotic-like abnormalities were more likely to have reduced diffusion capacity and reduced 6-minute-walk distance. Reticulations, as assessed by semiquantitative analysis, modestly improved across all time points, even between 15 months and 3 years. Qualitatively, most participants had stable fibrotic-like abnormalities across all time points, with 9% improving from 15 months to 3 years and none worsening. Lung parenchyma from transbronchial biopsies of five individuals with elevated fibrotic scores showed small airway histopathology, consistent with air trapping during expiration, and infrequent interstitial thickening and fibrosis. Conclusions: Despite modest improvements in radiologic fibrotic-like abnormalities 3 years after hospitalization, their continued presence and their association with reduced diffusion capacity and reduced walk distance highlight the long-term consequences of severe COVID-19, which may require further monitoring.
- Open Access
- 28 March 2025
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 11 (3)
Associations of albuminuria with interstitial lung abnormalities in older community-dwelling adults confounded by age
In two population-based cohorts, we did not find an independent relationship between albuminuria and ILA, with age emerging as a key confounding factor. Our results suggest there may be a common systemic pathology of aging that underlies albuminuria and ILA.Background: Pulmonary microvascular dysfunction has been suggested to be an early feature of interstitial lung changes, which may precede interstitial lung disease (ILD). The prospective association of albuminuria, a marker of endothelial dysfunction, with interstitial lung abnormalities (ILA) and high-attenuation areas (HAA) remains unexplored.Methods: The study included participants with available spot urinary albumin-creatinine ratio (UACR) and CT data for ILA and HAA enrolled in two independent cohorts, MESA (Multi-Ethnic Study of Atherosclerosis; n=2 248) and AGES-Reykjavik (Age, Gene/Environment Susceptibility-Reykjavik; n=3509). HAA were defined as the percentage of imaged lungs with attenuation between −600 and −250 Hounsfield units (MESA only). Regression modeling was performed to assess the associations of UACR with ILA and HAA, adjusted for anthropometric and demographic variables and kidney function. Cox proportional-hazard models were used to examine whether ILA modified the association between albuminuria and all-cause mortality.Results: Log-transformed UACR was significantly associated with ILA, with an odds ratio (OR) of 1.21 (95% CI, 1.12–1.30) in MESA and OR 1.13 (95% CI, 1.06–1.21) in AGES-Reykjavik. In multivariable-adjusted models incorporating age, albuminuria was no longer associated with ILA, nor with ILA progression in AGES-Reykjavik. In MESA, higher levels of albuminuria were associated with greater HAA (mean increase of 1.02% per 1-unit increment in log-transformed UACR, 95% CI, 1.01–1.02%), even after adjusting for covariates including age. Albuminuria was more strongly associated with death among those with ILA in MESA but not in AGES-Reykjavik.Conclusions: Albuminuria was not associated with ILA after accounting for chronological age. Our findings suggest that there may be a common systemic pathology of aging that underlies albuminuria and interstitial lung changes.
- 28 March 2025
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 11 (3)
Open AccessAssociations of albuminuria with interstitial lung abnormalities in older community-dwelling adults confounded by age
In two population-based cohorts, we did not find an independent relationship between albuminuria and ILA, with age emerging as a key confounding factor. Our results suggest there may be a common systemic pathology of aging that underlies albuminuria and ILA.Background: Pulmonary microvascular dysfunction has been suggested to be an early feature of interstitial lung changes, which may precede interstitial lung disease (ILD). The prospective association of albuminuria, a marker of endothelial dysfunction, with interstitial lung abnormalities (ILA) and high-attenuation areas (HAA) remains unexplored.Methods: The study included participants with available spot urinary albumin-creatinine ratio (UACR) and CT data for ILA and HAA enrolled in two independent cohorts, MESA (Multi-Ethnic Study of Atherosclerosis; n=2 248) and AGES-Reykjavik (Age, Gene/Environment Susceptibility-Reykjavik; n=3509). HAA were defined as the percentage of imaged lungs with attenuation between −600 and −250 Hounsfield units (MESA only). Regression modeling was performed to assess the associations of UACR with ILA and HAA, adjusted for anthropometric and demographic variables and kidney function. Cox proportional-hazard models were used to examine whether ILA modified the association between albuminuria and all-cause mortality.Results: Log-transformed UACR was significantly associated with ILA, with an odds ratio (OR) of 1.21 (95% CI, 1.12–1.30) in MESA and OR 1.13 (95% CI, 1.06–1.21) in AGES-Reykjavik. In multivariable-adjusted models incorporating age, albuminuria was no longer associated with ILA, nor with ILA progression in AGES-Reykjavik. In MESA, higher levels of albuminuria were associated with greater HAA (mean increase of 1.02% per 1-unit increment in log-transformed UACR, 95% CI, 1.01–1.02%), even after adjusting for covariates including age. Albuminuria was more strongly associated with death among those with ILA in MESA but not in AGES-Reykjavik.Conclusions: Albuminuria was not associated with ILA after accounting for chronological age. Our findings suggest that there may be a common systemic pathology of aging that underlies albuminuria and interstitial lung changes.
- Open Access
Imaging, Pulmonary Function, and Histopathologic Findings of Persistent Fibrosis in a Longitudinal Cohort Three Years after Severe COVID-19 Infection
Fibrotic-like abnormalities are present in 60% of a single-center, longitudinal, multi-ethnic cohort 3-years after severe COVID-19. They are independently associated with male sex, low BMI, shorter telomere length, increased severity of illness, and mechanical ventilation; Black race and asthma are protective. Participants with fibrotic-like abnormalities are more likely to have reduced diffusion capacity and 6-minute walk distance. Fibrotic-like abnormalities persist but modestly improve over time. Transbronchial biopsies show small airways histopathology, consistent with high prevalence of air trapping in expiration, and infrequent interstitial thickening. This study highlights the need for continued monitoring of patients with persistent fibrosis after severe COVID-19.
Open AccessImaging, Pulmonary Function, and Histopathologic Findings of Persistent Fibrosis in a Longitudinal Cohort Three Years after Severe COVID-19 Infection
Fibrotic-like abnormalities are present in 60% of a single-center, longitudinal, multi-ethnic cohort 3-years after severe COVID-19. They are independently associated with male sex, low BMI, shorter telomere length, increased severity of illness, and mechanical ventilation; Black race and asthma are protective. Participants with fibrotic-like abnormalities are more likely to have reduced diffusion capacity and 6-minute walk distance. Fibrotic-like abnormalities persist but modestly improve over time. Transbronchial biopsies show small airways histopathology, consistent with high prevalence of air trapping in expiration, and infrequent interstitial thickening. This study highlights the need for continued monitoring of patients with persistent fibrosis after severe COVID-19.
- Open Access
- 1 September 2024
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
- Vol. 21 (9) , 1219-1237
Postinfectious Pulmonary Complications: Establishing Research Priorities to Advance the Field: An Official American Thoracic Society Workshop Report
Continued improvements in the treatment of pulmonary infections have paradoxically resulted in a growing challenge of individuals with postinfectious pulmonary complications (PIPCs). PIPCs have been long recognized after tuberculosis, but recent experiences such as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic have underscored the importance of PIPCs following other lower respiratory tract infections. Independent of the causative pathogen, most available studies of pulmonary infections focus on short-term outcomes rather than long-term morbidity among survivors. In this document, we establish a conceptual scope for PIPCs with discussion of globally significant pulmonary pathogens and an examination of how these pathogens can damage different components of the lung, resulting in a spectrum of PIPCs. We also review potential mechanisms for the transition from acute infection to PIPC, including the interplay between pathogen-mediated injury and aberrant host responses, which together result in PIPCs. Finally, we identify cross-cutting research priorities for the field to facilitate future studies to establish the incidence of PIPCs, define common mechanisms, identify therapeutic strategies, and ultimately reduce the burden of morbidity in survivors of pulmonary infections.
- 1 September 2024
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
- Vol. 21 (9) , 1219-1237
Open AccessPostinfectious Pulmonary Complications: Establishing Research Priorities to Advance the Field: An Official American Thoracic Society Workshop Report
Continued improvements in the treatment of pulmonary infections have paradoxically resulted in a growing challenge of individuals with postinfectious pulmonary complications (PIPCs). PIPCs have been long recognized after tuberculosis, but recent experiences such as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic have underscored the importance of PIPCs following other lower respiratory tract infections. Independent of the causative pathogen, most available studies of pulmonary infections focus on short-term outcomes rather than long-term morbidity among survivors. In this document, we establish a conceptual scope for PIPCs with discussion of globally significant pulmonary pathogens and an examination of how these pathogens can damage different components of the lung, resulting in a spectrum of PIPCs. We also review potential mechanisms for the transition from acute infection to PIPC, including the interplay between pathogen-mediated injury and aberrant host responses, which together result in PIPCs. Finally, we identify cross-cutting research priorities for the field to facilitate future studies to establish the incidence of PIPCs, define common mechanisms, identify therapeutic strategies, and ultimately reduce the burden of morbidity in survivors of pulmonary infections.
Improved pulmonary function and exercise tolerance despite persistent pulmonary fibrosis over 1 year after severe COVID-19 infection
We conducted a prospective single-centre cohort study of 104 multi-ethnic severe COVID-19 survivors from the first wave of the pandemic 15 months after hospitalisation. Of those who were assessed at 4 and 15 months, improvement of ground glass opacities correlated with worsened fibrotic reticulations. Despite a high prevalence of fibrotic patterns (64%), pulmonary function, grip strength, 6 min walk distance and frailty normalised. Overall, dyspnoea, cough and exhaustion did not improve and were not correlated with pulmonary function or radiographic fibrosis at 15 months, suggesting non-respiratory aetiologies. Monitoring persistent, and often subclinical, fibrotic interstitial abnormalities will be needed to determine their potential for future progression.
Improved pulmonary function and exercise tolerance despite persistent pulmonary fibrosis over 1 year after severe COVID-19 infection
We conducted a prospective single-centre cohort study of 104 multi-ethnic severe COVID-19 survivors from the first wave of the pandemic 15 months after hospitalisation. Of those who were assessed at 4 and 15 months, improvement of ground glass opacities correlated with worsened fibrotic reticulations. Despite a high prevalence of fibrotic patterns (64%), pulmonary function, grip strength, 6 min walk distance and frailty normalised. Overall, dyspnoea, cough and exhaustion did not improve and were not correlated with pulmonary function or radiographic fibrosis at 15 months, suggesting non-respiratory aetiologies. Monitoring persistent, and often subclinical, fibrotic interstitial abnormalities will be needed to determine their potential for future progression.
- Open Access
Molecular Pathophysiology of Cardiac Injury and Cardiac Microthrombi in Fatal COVID-19: Insights from Clinico-histopathologic and Single Nuclei RNA Sequencing Analyses
Cardiac injury is associated with critical COVID-19, yet its etiology remains debated. To elucidate the pathogenic mechanisms of COVID-19-associated cardiac injury, we conducted a single-center prospective cohort study of 69 COVID-19 decedents. Of six cardiac histopathologic features, microthrombi was the most commonly detected (n=48, 70%). We tested associations of cardiac microthrombi with biomarkers of inflammation, cardiac injury, and fibrinolysis and with in-hospital antiplatelet therapy, therapeutic anticoagulation, and corticosteroid treatment, while adjusting for multiple clinical factors, including COVID-19 therapies. Higher peak ESR and CRP during hospitalization were independently associated with higher odds of microthrombi. Using single nuclei RNA-sequence analysis, we discovered an enrichment of pro-thrombotic/anti-fibrinolytic, extracellular matrix remodeling, and immune-potentiating signaling amongst cardiac fibroblasts in microthrombi-positive COVID-19 hearts relative to microthrombi-negative COVID-19. Non-COVID-19 non-failing hearts were used as reference controls. Our cumulative findings identify the specific transcriptomic changes in cardiac fibroblasts as salient features of COVID-19-associated cardiac microthrombi.
Open AccessMolecular Pathophysiology of Cardiac Injury and Cardiac Microthrombi in Fatal COVID-19: Insights from Clinico-histopathologic and Single Nuclei RNA Sequencing Analyses
Cardiac injury is associated with critical COVID-19, yet its etiology remains debated. To elucidate the pathogenic mechanisms of COVID-19-associated cardiac injury, we conducted a single-center prospective cohort study of 69 COVID-19 decedents. Of six cardiac histopathologic features, microthrombi was the most commonly detected (n=48, 70%). We tested associations of cardiac microthrombi with biomarkers of inflammation, cardiac injury, and fibrinolysis and with in-hospital antiplatelet therapy, therapeutic anticoagulation, and corticosteroid treatment, while adjusting for multiple clinical factors, including COVID-19 therapies. Higher peak ESR and CRP during hospitalization were independently associated with higher odds of microthrombi. Using single nuclei RNA-sequence analysis, we discovered an enrichment of pro-thrombotic/anti-fibrinolytic, extracellular matrix remodeling, and immune-potentiating signaling amongst cardiac fibroblasts in microthrombi-positive COVID-19 hearts relative to microthrombi-negative COVID-19. Non-COVID-19 non-failing hearts were used as reference controls. Our cumulative findings identify the specific transcriptomic changes in cardiac fibroblasts as salient features of COVID-19-associated cardiac microthrombi.
- Top Cited Papers
- 22 March 2021
- Published by Springer Nature in Nature Medicine
- Vol. 27 (4) , 601-615
Post-acute COVID-19 syndrome
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the pathogen responsible for the coronavirus disease 2019 (COVID-19) pandemic, which has resulted in global healthcare crises and strained health resources. As the population of patients recovering from COVID-19 grows, it is paramount to establish an understanding of the healthcare issues surrounding them. COVID-19 is now recognized as a multi-organ disease with a broad spectrum of manifestations. Similarly to post-acute viral syndromes described in survivors of other virulent coronavirus epidemics, there are increasing reports of persistent and prolonged effects after acute COVID-19. Patient advocacy groups, many members of which identify themselves as long haulers, have helped contribute to the recognition of post-acute COVID-19, a syndrome characterized by persistent symptoms and/or delayed or long-term complications beyond 4 weeks from the onset of symptoms. Here, we provide a comprehensive review of the current literature on post-acute COVID-19, its pathophysiology and its organ-specific sequelae. Finally, we discuss relevant considerations for the multidisciplinary care of COVID-19 survivors and propose a framework for the identification of those at high risk for post-acute COVID-19 and their coordinated management through dedicated COVID-19 clinics.
- 22 March 2021
- Published by Springer Nature in Nature Medicine
- Vol. 27 (4) , 601-615
Top Cited PapersPost-acute COVID-19 syndrome
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the pathogen responsible for the coronavirus disease 2019 (COVID-19) pandemic, which has resulted in global healthcare crises and strained health resources. As the population of patients recovering from COVID-19 grows, it is paramount to establish an understanding of the healthcare issues surrounding them. COVID-19 is now recognized as a multi-organ disease with a broad spectrum of manifestations. Similarly to post-acute viral syndromes described in survivors of other virulent coronavirus epidemics, there are increasing reports of persistent and prolonged effects after acute COVID-19. Patient advocacy groups, many members of which identify themselves as long haulers, have helped contribute to the recognition of post-acute COVID-19, a syndrome characterized by persistent symptoms and/or delayed or long-term complications beyond 4 weeks from the onset of symptoms. Here, we provide a comprehensive review of the current literature on post-acute COVID-19, its pathophysiology and its organ-specific sequelae. Finally, we discuss relevant considerations for the multidisciplinary care of COVID-19 survivors and propose a framework for the identification of those at high risk for post-acute COVID-19 and their coordinated management through dedicated COVID-19 clinics.
- Open Access
Pulmonary Fibrosis after COVID-19 is Associated with Severity of Illness and Blood Leukocyte Telomere Length
The risk factors for development of fibrotic interstitial lung abnormalities (ILA) after severe COVID-19 are incompletely described and the extent to which CT findings correlate with symptoms and physical function after hospitalization remain unclear. At 4 months after hospitalization, fibrotic ILA was more common in those who underwent mechanical ventilation (72%) than in those who did not (20%). We demonstrate that severity of initial illness, duration of mechanical ventilation, lactate dehydrogenase on admission, and leukocyte telomere length are independent risk factors for fibrotic ILA. These fibrotic changes correlate with lung function, cough and measures of frailty, but not with dyspnea.
Open AccessPulmonary Fibrosis after COVID-19 is Associated with Severity of Illness and Blood Leukocyte Telomere Length
The risk factors for development of fibrotic interstitial lung abnormalities (ILA) after severe COVID-19 are incompletely described and the extent to which CT findings correlate with symptoms and physical function after hospitalization remain unclear. At 4 months after hospitalization, fibrotic ILA was more common in those who underwent mechanical ventilation (72%) than in those who did not (20%). We demonstrate that severity of initial illness, duration of mechanical ventilation, lactate dehydrogenase on admission, and leukocyte telomere length are independent risk factors for fibrotic ILA. These fibrotic changes correlate with lung function, cough and measures of frailty, but not with dyspnea.